Recent therapeutic trends and promising targets in triple negative breast cancer

Soo Yeon Hwang, Seojeong Park, Youngjoo Kwon

Research output: Contribution to journalReview articlepeer-review

160 Scopus citations


Breast cancer accounts for 25% of all types of cancer in women, and triple negative breast cancer (TNBC) comprises around 15~20% of breast cancers. Conventional chemotherapy and radiation are the primary systemic therapeutic strategies; no other FDA-approved targeted therapies are yet available as for TNBC. TNBC is generally characterized by a poor prognosis and high rates of proliferation and metastases. Due to these aggressive features and lack of targeted therapies, numerous attempts have been made to discover viable molecular targets for TNBC. Massive cohort studies, clinical trials, and in-depth analyses have revealed diverse molecular alterations in TNBC; however, controversy exists as to whether many of these changes are beneficial or detrimental in caner progression. Here we review the complicated tumorigenic processes and discuss critical findings and therapeutic trends in TNBC with a focus on promising therapeutic approaches, the clinical trials currently underway, and potent experimental compounds under preclinical and evaluation.

Original languageEnglish
Pages (from-to)30-57
Number of pages28
JournalPharmacology and Therapeutics
StatePublished - Jul 2019

Bibliographical note

Funding Information:
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) ( 2018R1A5A2025286 ) and ( 2018R1A2B2016115 ).

Publisher Copyright:
© 2019 The Authors


  • Clinical trials
  • Experimental targets
  • Metastatic triple negative breast cancer (mTNBC)
  • Preclinical implication
  • Small molecules
  • Targeted therapy


Dive into the research topics of 'Recent therapeutic trends and promising targets in triple negative breast cancer'. Together they form a unique fingerprint.

Cite this